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A B S T R A C T   
Obesity-induced insulin resistance is a risk factor for diabetes and cardiovascular disease. However, the mech-
anisms underlying endothelial senescence in obesity, and how it impacts obesity-induced insulin resistance 
remain incompletely understood. In this study, transcriptome analysis revealed that the long non-coding RNA 
(lncRNA) Maternally expressed gene 3 (Meg3) is one of the top differentially expressed lncRNAs in the vascular 
endothelium in diet-induced obese mice. Meg3 knockdown induces cellular senescence of endothelial cells 
characterized by increased senescence-associated β–galactosidase activity, increased levels of endogenous su-
peroxide, impaired mitochondrial structure and function, and impaired autophagy. Moreover, Meg3 knockdown 
causes cellular senescence of hepatic endothelium in diet-induced obese mice. Furthermore, Meg3 expression is 
elevated in human nonalcoholic fatty livers and nonalcoholic steatohepatitis livers, which positively correlates 
with the expression of CDKN2A encoding p16, an important hallmark of cellular senescence. Meg3 knockdown 
potentiates obesity-induced insulin resistance and impairs glucose homeostasis. Insulin signaling is reduced by 
Meg3 knockdown in the liver and, to a lesser extent, in the skeletal muscle, but not in the visceral fat of obese 
mice. We found that the attenuation of cellular senescence of hepatic endothelium by ablating p53 expression in 
vascular endothelium can restore impaired glucose homeostasis and insulin signaling in obesity. In conclusion, 
our data demonstrate that cellular senescence of hepatic endothelium promotes obesity-induced insulin resis-
tance, which is tightly regulated by the expression of Meg3. Our results suggest that manipulation of Meg3 
expression may represent a novel approach to managing obesity-associated hepatic endothelial senescence and 
insulin resistance.   
1. Introduction 
Cellular senescence is a stable form of cell cycle arrest that can be 
induced by various stressors. Senescent cells display a number of hall-
marks, including DNA damage, mitochondrial dysfunction, and 
increased cyclin-dependent kinase inhibitors and senescence-associated 
β-galactosidase (SA-β-gal) activity [1–4]. It is increasingly recognized 
that cellular senescence is heterogeneous and cell-specific with pleio-
tropic function [1,5–7]. Senescent cells are required for tissue remod-
eling and morphogenesis during embryonic development [8,9], are 
essential for wound healing [10], and promote heart regeneration after 
injury [11,12]. In contrast, targeted elimination of senescent cells pre-
vents neurodegeneration [13], extends healthy life [14], and prevents 
Type 1 diabetes [15]. Recently, it was demonstrated that elimination of 
senescent cells improved glucose tolerance, enhanced insulin sensitivity, 
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reduced macrophage accumulation in adipose tissue, lowered circu-
lating inflammatory mediators, and promoted adipogenesis in obese 
mice [16]. These results indicate that cellular senescence is a causal 
factor in obesity-related inflammation and metabolic derangements. 
However, the role of senescent endothelial cells (ECs) in regulating the 
induction and exacerbation of obesity-induced insulin resistance is 
largely unknown [17]. 
Long non-coding RNAs (lncRNAs) are a subgroup of non-protein 
coding RNA transcripts that regulate gene expression in a range of 
signaling pathways, and changes in their expression and function 
contribute to the pathogenesis of human diseases [18–20] Emerging 
studies have shown that they are important regulators of cell stress re-
sponses [19–22]. We found that lncRNA Maternally expressed gene 3 
(Meg3) protects endothelial function by regulating the DNA damage 
response [23]. In the present study, we identified Meg3 as a top differ-
entially expressed lncRNA in the vascular endothelium of obese mice, 
and examined the role of Meg3 in regulating obesity-induced endothe-
lial senescence and insulin resistance. We found that the loss of Meg3 
induced hepatic endothelial senescence, and impaired glucose homeo-
stasis and insulin signaling in obese mice. Meg3 knockdown induced 
cellular senescence by impeding mitochondrial function, facilitating the 
formation of mitochondria-derived reactive oxygen species, and 
impairing autophagy. Our findings demonstrate that hepatic endothelial 
senescence promotes obesity-induced insulin resistance. 
2. Materials and methods 
2.1. Mice 
All methods reported herein were carried out in accordance with 
relevant guidelines and regulations of the University of Nebraska – 
Lincoln (UNL). All experimental protocols were reviewed and approved 
by UNL Institutional Biosafety Committee (Protocol Number: IBC788). 
Mouse experiments were performed in accordance with Public Health 
Service (PHS) animal welfare policy, the principles of the NIH Guide for 
the Care and Use of Laboratory Animals, and the policies and procedures 
at UNL. All animals were maintained in the UNL’s centralized Life Sci-
ences Annex facility, which is accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care. Mouse experiments 
were performed under Institutional Animal Care and Use Committee 
(IACUC) Protocol# 1820 (breeding) and Protocol# 1819 (experiments). 
C57BL/6J mice were ordered from the Jackson Laboratory (stock 
#000664). The p53 floxed mice (Jackson stock #008462; p53fl/fl) were 
bred with Cdh5CreERT2 Cre mice [24,25] for two or three rounds to 
generate p53fl/fl-Cre mice (p53 iECKO). A mouse model of diet-induced 
obesity was used in our studies. It has been widely used to dissect mo-
lecular mechanisms in obesity and obesity-impaired insulin signaling 
[26–31]. To examine Meg3 expression in lean and obese mice, two 
groups of C57BL/6J mice were used: one group was fed a high-fat diet 
(HFD; Research Diets D12492, 60% calories from fat) at 7 weeks of age 
for 4 or 8 weeks, and the second group was fed a control diet for D12492 
(Research Diets D12450J, 10% calories from fat, matching sucrose and 
protein to D12492). To examine the effects of Meg3 on cellular senes-
cence and glucose homeostasis, C57BL/6J mice or other mouse lines 
(see below) were fed a HFD (60% calories from fat, Research Diets 
D12492) at 7 weeks of age for 12 weeks. The p53 floxed mice or p53 
iECKO mice were injected daily with tamoxifen (Sigma T5648; intra-
peritoneal 50 mg/kg) in corn oil for 5 days at 3–4 weeks of age as 
described [32]. Immediately after the last tamoxifen injection, p53fl/fl or 
p53 iECKO mice were fed a 60% HFD for 12 weeks. At Week 5 on HFD, 
C57BL/6J, p53fl/fl, or p53 iECKO mice were randomly assigned into two 
groups and injected weekly with either negative control gapmeRs or 
Meg3 gapmeRs (intravenous 5 or 10 mg/kg) for 5 or 6 weeks. In vivo 
ready mouse Meg3 gapmeR (5′-TCATCAGTCAGTAGGT-3′) and LNA 
antisense negative control A (5′-AACACGTCTATACGC -3′) were pur-
chased from Qiagen. To examine the effects of Meg3 knockdown on 
insulin signaling cascade in vivo, the mice were injected with insulin 
(0.75 U/kg Humulin R) after overnight fasting. The tissues were 
collected at 10 min after insulin injection. 
2.2. Human liver specimens 
Gene expression in human liver specimens was performed under the 
Institutional Review Board (IRB) Approval #: 20190419315EX. Normal 
human liver and pathologic human liver were obtained through the 
Liver Tissue Cell Distribution System, Minneapolis, MN. 
2.3. Glucose tolerance and insulin tolerance tests 
Glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) were 
performed as described in our previous studies [33]. For GTTs, mice 
were fasted for 12 h, and then injected with D-glucose (intraperitoneal 
1.0 g per kg of body weight). ITTs were performed on mice after 6 h of 
fasting. Insulin (0.75 U/kg Humulin R) were given to mice by intra-
peritoneal injection. Blood glucose levels were measured before injec-
tion and at 15, 30, 60, 90, and 120 min after glucose or insulin injection 
using One Touch Ultra glucometer. 
2.4. Cell culture 
Human Umbilical Vein Cells (HUVECs) (cc-2159) were obtained 
from Lonza Group Ltd. and cultured in EC growth medium EGM-2 (cc- 
3162). Cells used for all experiments were subcultured <8 times. 
HUVECs (90,000/well) were plated into 12-well plates, transfected with 
10 nM gapmeRs (LNA-modified antisense oligonucleotides) when cells 
reached 80–90% confluency. Lipofectamine 2000 (Thermo Fisher Cat# 
11668019) was used following the manufacturer instructions. Human 
Meg3 gapmeR (5′-GTAAGACAAGCAAGAG-3′), and LNA antisense 
negative control A (5′-AACACGTCTATACGC -3′) were purchased from 
Qiagen. 
For western blot analysis of p62 and LC3 II, HUVECs were treated 
with 100 nM Bafilomycin A1 (Sigma Cat# B1793) for 4 h. For SA-β-gal 
staining, cells were treated with 20 nM rapamycin (Sigma Cat# R8781) 
for 48 h. 
2.5. Endothelial cell isolation 
For the sample preparation for RNA-seq, C57BL/6J mice were or-
dered from the Jackson Laboratory (stock #000664). Mice were fed on a 
high-fat diet (60% calories from fat, Research Diets D12492) at 8 weeks 
Abbreviations 
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of age for 5 weeks (6 mice; n = 2 mice each sample). Mice fed on a 
regular chow diet were used as controls (9 mice; n = 3 mice each 
sample). For other experiments, mice were fed on a 60% HFD or treated 
as indicated before EC isolation. The method for isolation of mouse ECs 
was modified from previous studies [33–36]. Mice were euthanized by 
30% isoflurane. Livers, eWATs, or skeletal muscles were harvested, 
washed with 1 x dPBS to remove any contaminants. Tissues were minced 
into small pieces with scissors followed by digestion with 10 ml diges-
tion buffer (collagenase type 2, Worthington-Biochem, Cat# LS004177, 
1mg/ml in DMEM/F12; dipase II, Roche, Cat# 04942078001, 1 mg/ml 
in DMEM/F12) for 40 min in a 37 ◦C shaker. Cell slurry was transferred 
onto a 100 μm cell strainer pre-wet with equal volume of wash medium 
(DMEM/F12 medium with 10%FBS), then span at 500×g for 10 min. 
Supernatant was gently aspirated and discarded, and cell pellet was 
re-suspended in 10 ml wash medium followed by second filtering with 
40 μm cell strainer and spinning at 500×g for 10 min. Supernatant was 
gently aspirated and cell pellet was mixed with 1 ml incubation buffer 
(0.1% BSA, 2 mM EDTA and 0.5% FBS in 1 x dPBS). Cell suspension was 
incubated with sheep anti-rat IgG Dynabeads (Thermo Fisher, Cat# 
11035) coated with PECAM-1 antibodies (Becton Dickinson Co, Cat# 
557355) and tumbled at 4 ◦C for 15 min. After incubation, beads were 
separated by using magnetic separation rack (NEB, Cat# S1509S), and 
washed with 1 ml of 0.1% BSA in PBS twice, then mixed with 500 μl 
TRIzol reagent for each sample followed by RNA extraction according to 
the manufacturer’s instructions. 
2.6. Senescence-associated β-gal staining 
HUVECs were seeded into two T25 flasks (750,000 cells/flask), and 
transfected with 10 nM negative control or Meg3 gapmeRs using Lip-
ofectamine 2000 on the next day. After 16 h, medium was replaced and 
changed every two days. On day 5 after transfection, cells were plated to 
12-well plate (90,000 cells/well). For double knockdown of p53 and 
Meg3, HUVECs (750,000 cells/flask) were seeded into two T25 flasks. 
Cells were transduced by lentiviral control shRNA or p53 shRNA 
generated as described in our previous studies [23]. After 24 h, cells 
were split to two flasks. On the next day, cells were transfected with 
negative control or Meg3 gapmeRs using Lipofectamine 2000. Medium 
were changed at 16 h post-transfection and cells were plated into 
12-well plate (90,000 cells/well) at 72 h after transfection. β-galacto-
sidase staining was performed using Senescence β-galactosidase Staining 
Kit according to the manufacturer’s instructions (Cell Signaling Tech-
nology, #9860) at 96 h post-transfection. 
2.7. MitoSOX staining 
To measure mitochondrial superoxide production, HUVECs were 
stained with MitoSOX™ Red superoxide radical-specific reagent as 
described [37–39]. HUVECs were incubated with 1 μM MitoSOX dye 
(Thermo Fisher, Cat# M36008) in 1 x HBSS with Ca2+ and Mg2+ for 10 
min, washed three times with 1 x HBSS with Ca2+ and Mg2+. Cells were 
trypsinized and re-suspended in 1 x HBSS buffer with Ca2+ and Mg2+ for 
flow cytometry analysis immediately [40,41]. MitoSOX was excited 
with 488 nm laser, and Texas red filter (610/40 nm) was used to detect 
the emission by flow cytometry. 
2.8. Electron paramagnetic resonance (EPR) spectroscopy 
HUVECs were transfected with 10 nM control gapmeRs or Meg3 
gapmeRs. 40 h post-transfection, cells were collected for EPR as 
described previously [42,43]. After removing cell culture media, cells 
were incubated in 1 mL of Krebs-HEPES Buffer (pH 7.4) containing (in 
mM): 99 NaCl, 4.69 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, 1.03 
KH2PO4, 5.6 D-glucose, 20 HEPES, and supplemented with the metal 
chelators deferoxamine (25 μM) and diethyldithiocarbamic acid sodium 
salt (5 μM). The superoxide-sensitive EPR spin probe, 
1-hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) 
was added to get 200 μM final concentration, and incubated for 30 min 
at 37 ◦C. Then, 900 μl of buffer was removed and cells were collected by 
scraping in the remaining 100 μl. The sample (50 μl) was then loaded 
into a glass capillary tube and inserted into the capillary holder of a 
Bruker e-scan EPR spectrometer. The following EPR spectrometer set-
tings were used: field sweep width, 60.0 G; microwave frequency, 9.74 
kHz; microwave power, 21.90 mW; modulation amplitude, 2.37 G; 
conversion time, 10.24 ms; time constant, 40.96 ms. The EPR spectrum 
amplitude, which is directly proportional to the levels of free radicals in 
the sample, was normalized to cell number in each sample. 
2.9. Assessment of mitochondrial bioenergetics 
To measure mitochondrial respiration, transfected HUVECs were 
plated in 24-well Seahorse culture plates (95% confluency, 20,000 cells/ 
well) one day prior to measurement. For O2 consumption rate (OCR) 
measurement, cell culture media were changed to modified XF assay 
medium containing 10 mM glucose, 1 mM sodium pyruvate and 2 mM L- 
glutamine. Following 1 h incubation at 37 ◦C without CO2, OCR were 
measured using Seahorse XFe24 extracellular flux analyzer according to 
manufacturer’s instruction in response to the respiratory chain in-
hibitors: 1 μM Oligomycin, 1 μM FCCP, 1.5 μM antimycin A and 3 μM 
rotenone. 
2.10. RNA sequencing and analysis 
Total RNAs were extracted from the isolated ECs using TRIzol re-
agent (ThermoFisher, Cat# 15596018) according to the manufacturer’s 
instructions. RNA samples were in triplicates. RNA-seq analysis was 
performed by Genewiz (Formerly Beckman Coulter Genomics). Ribo-
somal RNAs were depleted using TruSeq Stranded Total RNA with Ribo- 
Zero Gold kit. Then, stranded RNA-seq automated libraries were con-
structed for sequencing on an Illumina HiSeq 2500 (2 x 100 bp). After 
obtaining raw reads, FastQC was used to analyze the quality of the reads. 
The number of quality control-passed reads is at least 45 million per 
sample. Tophat2 and bowtie [44–46] were used to map the reads to the 
genome, GRCh38, Ensembl release 82 [47], and cufflinks [48] was used 
to determine transcript expression. Cuffdiff [49] was used to generate 
FPKM values and edgeR [50–53] was used for differential expression 
analysis. Heatmap was generated using the R pheatmap package, and 
genes were ranked on logFC of FPKMs. 
2.11. Immunofluorescence and imaging 
Tissues were fixed in 10% formalin (Sigma, Cat# HT5012-60 ML) for 
24 h at 4 ◦C. The fixed tissues were immersed in 10% sucrose for 2 days 
and subsequently in 30% sucrose for 2 days. Then the tissues were 
embedded in cryomolds with optimal cutting temperature compound 
(Fisher Scientific, Cat# 4585) and allowed to freeze on dry ice. Frozen 
tissues were sectioned using cryostat microtome and the sections were 
mounted on poly-lysine coated slides (Thermo Fisher, Cat# P4981-001). 
The slides with mounted tissue sections were immersed in 1:1 solution of 
acetone:methanol mixture at 4 ◦C for 10 min and then washed with 1 x 
dPBS containing 0.3% Triton X-100 (PBST) three times with 5 min for 
each. The sections were then blocked with 0.3% PBST containing 5% 
goat serum and 1% BSA. Primary antibodies at dilutions, 1:100 for p21 
(Abcam, Cat# Ab188224), 1:100 for CD31 (BD, Cat# 550274), 1:500 for 
CD68 (BioLegend, Cat#137001), 1:2000 for Mac-2 (Cedarlane, Cat# 
CL8942AP), 1:500 for perilipin (Cell Signaling Technology, Cat# 9349S) 
were used for overnight staining at 4 ◦C. Slides were washed three times 
with 0.3% PBST for 5 min each. Subsequently, the slides were incubated 
with appropriate secondary antibodies at dilution, 1: 200 for DyLight® 
549 anti-Mouse IgG (Vector, Cat# DI-2549); 1:200 for DyLight® 649 
anti-Rabbit IgG (Vector, Cat# DI-1649); 1:200 for Cy™3 AffiniPure goat 
anti-Rat IgG (H + L) (Jackson Immunoresearch, Cat# 112-165-167) 
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with DAPI for nuclear staining for 1 h at room temperature. After the 
slides were washed three times with 0.3% PBST, 5 min each, they were 
mounted with coverslips using Fluoromount-G® (Southern biotech, 
Cat# 0100–01) and allowed to dry overnight in dark at room temper-
ature. Images were captured using Fluorescent microscope. Three 
random fields per tissue sample were captured and the images were 
analyzed for appropriate staining. 
2.12. Quantitative real-time PCR (qPCR) 
RNA was collected from HUVECs or mouse tissues using TRIzol Re-
agent (Thermo Fisher, Cat# 15596026) according to the manufacturer’s 
instructions. 1 μg of RNA was converted to cDNAs using the High Ca-
pacity cDNA Reverse Transcription Kit (Thermo Fisher, Cat# 4368814). 
qPCRs were conducted in the CFX Connect Real Time System (BioRad) 
using 2x SYBR Green qPCR Master Mix (Bimake, Cat# B21203). Data 
was normalized by the ΔΔCt method [54]. Primer sequences are listed in 
the Supplementary Table 1. 
2.13. Western blot analysis 
Mouse tissues were homogenized in RIPA buffer (25 mM Tris-HCl pH 
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) that 
was supplemented with protease and phosphatase inhibitors. Cell ly-
sates were collected after spinning at 13,000×g for 10 min. Protein 
concentrations were measured by using the Pierce BCA Protein Assay Kit 
(Thermo Fisher). 10 μg of protein was loaded per sample and the sam-
ples were separated by SDS-PAGE using a 10% or 12% acrylamide gel. 
After SDS-PAGE, the samples were transferred to Immun-Blot PVDF 
Membranes using the Trans Blot Turbo Transfer System (BioRad; 25 V, 
1.0 A, 30 min). After blocking with 5% nonfat milk in TBST, membranes 
were incubated with corresponding antibodies. Then the blot was pro-
bed with HRP-conjugated anti-rabbit (Cell Signaling Technology, Cat# 
7074). ECL Plus Western blotting detection reagents (GE Healthcare, 
Cat# RPN2132) were used to visualize proteins. ImageJ software (Na-
tional Institutes of Health) was used to analyze protein abundance. 
Antibodies used in this study include anti-Phospho-Akt (Ser473) (Cell 
Signaling Technology, Cat# 4060S), anti-Akt (Cell Signaling Technol-
ogy, Cat# 4691S), anti-p62 (MBL international, Cat# PM045), anti- 
LC3B (Cell Signaling Technology, Cat# 3868S), anti-Phospho-IGF-I Re-
ceptor β (Tyr1135/1136)/Insulin Receptor β (Tyr1150/1151) (Cell 
Signaling Technology, Cat# 3024S), anti-Insulin Receptor β (Cell 
Signaling Technology, Cat# 3025S), anti-p53 (Cell Signaling Technol-
ogy, Cat# 9282S), and anti-GAPDH (Cell Signaling Technology, Cat# 
5174). Protease inhibitor cocktail tablets were from Roche Diagnostics. 
Phosphatase inhibitor was from Active Motif. 
2.14. Live cell imaging 
Live cell imaging was carried out using a Nikon A1R-TiE (inverted) 
confocal live-cell imaging system. An incubation chamber was used to 
maintain the live cell conditions (5% CO2 and 37 ◦C with humidity). 
Cells cultured in a 35 mm glass bottom dish were used for imaging using 
100x (NA 1.4) oil immersion lens with the help of NIS elements software 
by sequential scanning, where applicable. For mitochondrial network 
staining, cells were incubated with 300 nM MitoTracker Deep Red dye at 
37 ◦C for 10 min in 1 x HBSS with calcium and magnesium and washed 
twice before imaging. Cells were excited by 640 nm laser and emissions 
were collected at 640–690 nm range. HUVECs were also stained with 
500 nM MitoTracker Green for 30 min and treated with 10 μM FCCP for 
10 min for live cell imaging. For membrane potential staining, cells were 
stained with 5 μg/ml JC-1 dye at 37 ◦C for 15 min in 1 x HBSS with 
calcium and magnesium and washed twice. JC1 was excited by the 488 
nm and 561 nm lasers, and emissions were collected between 500 - 550 
nm and 570–620 nm. Nuclei stained with Hoechst was excited at 405 nm 
wavelength laser and emission was collected between 425 and 475 nm. 
Mitochondrial structure was analyzed using a custom-modified NIH 
ImageJ macro [55,56]. Form factor = Perimeter^2/(4 × Pi × area). 
Mitochondrial perimeter is defined as the number of pixels forming the 
boundary of a mitochondrial region. 
2.15. ELISA 
Plasma levels of insulin, adiponectin, TNF-α, MCP-1 were measured 
by Eve Technologies Corp., and plasma levels of AST and ALT were 
measured by the Biomedical and Obesity Research Core at UNL. 
2.16. Statistical analysis 
For two-group comparisons, paired or unpaired Student’s t-test was 
used for data that passed normality and equal variance test; otherwise, a 
nonparametric Mann-Whitney U test will be used. For multiple groups, 
one-way ANOVA followed by Tukey’s post hoc test was used for data 
that passed normality and equal variance test; otherwise one-way 
ANOVA followed by Holm’s post hoc test will be used. Normality will 
be checked with the Kolmogorov-Smirnov test. An alpha level of 0.05 
were used to determine significant differences, and data are reported as 
mean ± SEM. 
3. Results 
3.1. Endothelial Meg3 expression is elevated in obesity 
To identify differentially expressed lncRNAs in vascular endothelium 
in obese mice, the ECs of epididymal white adipose tissues (eWATs) 
were isolated from lean and obese mice for global transcriptomic anal-
ysis using RNA-seq (Fig. 1A). The bioinformatics analysis identified 34 
differentially expressed lncRNAs using edgeR (Fig. 1B). Among these 
lncRNA transcripts, Meg3 is one of the top induced lncRNAs (Fig. 1B). 
We examined Meg3 expression in the vascular endothelium of major 
insulin target organs in lean and obese mice. After 4 weeks of high-fat 
diet (HFD), Meg3 expression was induced by 1.6-, 1.5-, and 1.7-fold in 
ECs isolated from eWATs, skeletal muscles, and livers of obese mice, 
respectively; after 8 weeks of HFD, Meg3 expression was induced by 2.0- 
, 1.9-, and 2.3-fold, respectively (Fig. 1C). Meg3 expression is higher in 
the ECs from eWAT compared to those from the skeletal muscle or liver 
(Fig. 1D). Meg3 in situ hybridization revealed that the majority of Meg3 
is expressed in the nucleus of mouse and human adipose tissues co- 
localizing with the nuclei of adjacent CD31 positive cells (Fig. S1). 
These data demonstrate that Meg3 is induced in the vascular endothe-
lium of diet-induced obese mice. 
3.2. Meg3 knockdown causes cellular senescence in HUVECs 
Meg3 expression is elevated in senescent HUVECs compared with 
early passage cells [57], and in HUVECs exposed to oxidative stress [58] 
and hypoxia [59]. We have shown that DNA damaging agents induced 
Meg3 expression in HUVECs in a p53-dependent manner, and Meg3 
knockdown induced DNA damage and inhibited EC proliferation [23]. 
Meg3 knockdown also reduced the telomere length in HUVECs [60]. 
However, the role of Meg3 in cellular senescence has not been thor-
oughly investigated. 
Here, we studied the effects of Meg3 on cellular senescence by 
examining several complementary hallmarks of cellular senescence in 
HUVECs, including SA-β-gal activity, mitochondrial dysfunction, and 
autophagy (Fig. 2). SA-β-gal activity is one of the commonly used marker 
for senescence in vitro and in vivo [61,62]. We found that Meg3 knock-
down increased the levels of SA-β-gal activity by 2.7-fold (Fig. 2A). 
Mitochondrial dysfunction and mitochondria-derived superoxide are 
key hallmarks of cellular senescence [63–66]. We asked whether Meg3 
knockdown increases levels of superoxide in HUVECs. 
Superoxide-specific MitoSOX staining and flow cytometry revealed that 
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HUVECs with Meg3 knockdown showed a marked increase in superox-
ide (Fig. 2B). Free radicals, primarily superoxide, were measured by 
Electron Paramagnetic Resonance (EPR) Spectroscopy [42,43]. Consis-
tent with the MitoSOX staining data, HUVECs with Meg3 knockdown 
displayed a significant increase in superoxide levels compared to control 
cells (Fig. 2C), as indicated by an increase in the EPR spectrum ampli-
tude. We examined the effects of Meg3 knockdown on mitochondrial 
bioenergetic function in HUVECs including mitochondrial respiration 
and cellular glycolysis. Meg3 knockdown reduced the basal mitochon-
drial O2 consumption rate and the maximal respiration capacity 
(Fig. 2D). Meg3 knockdown did not affect the extracellular acidification 
rate, which is a proxy to cellular glycolytic flux (Fig. S2). We next sought 
to determine the effect of Meg3 knockdown on mitochondrial 
morphology using a custom-modified NIH Image J macro [55,56]. We 
found that mitochondria were predominantly fragmented in HUVECs 
with Meg3 knockdown (Fig. 2E), which is comparable with the effects of 
FCCP, a chemical uncoupler that potently induces mitochondrial frag-
mentation (Fig. S3). These changes in mitochondrial network are asso-
ciated with the attenuated mitochondrial membrane potential in 
HUVECs with Meg3 knockdown (Fig. 2F). These data demonstrate that 
Meg3 knockdown impairs mitochondrial structure and function. Finally, 
we examined the effects of Meg3 knockdown on autophagy because 
impaired autophagy can promote cellular senescence in ECs [67,68]. 
The expression of both p62 and LC3-II were induced by Meg3 knock-
down in HUVECs under basal condition (Fig. 2G). When cells were 
treated with Bafilomycin A1, both p62 and LC3-II accumulation were 
comparable between control cells and cells with Meg3 knockdown, 
though the expression of p62 showed a tendency towards statistical 
significance (Fig. 2G). Our data demonstrate that Meg3 knockdown al-
ters autophagic flux likely by impairing autophagy in HUVECs. More-
over, the activation of autophagy by rapamycin attenuated Meg3 
knockdown-induced SA-β-gal activity in HUVECs, suggesting that 
Meg3 knockdown promotes cellular senescence likely by impairing 
autophagy in HUVECs (Fig. 2H). 
In summary, these data along with our published results showing 
that Meg3 knockdown induced DNA damage and inhibited cell prolif-
eration [23] demonstrate that Meg3 prevents cellular senescence in 
HUVECs. 
3.3. Meg3 knockdown causes cellular senescence in hepatic endothelium 
in obesity 
Our data suggest that Meg3 is required to limit endothelial senes-
cence in vitro. This prompted us to ask if Meg3 knockdown affects 
cellular senescence in mice. We used a mouse model of diet-induced 
obesity in our studies. In this model, mice develop obesity, elevated 
adiposity, glucose intolerance, moderate insulin resistance, and hyper-
insulinemia compared with lean mice, which mimics human metabolic 
derangements observed in obesity [69–73]. We employed locked nucleic 
acid-modified antisense oligonucleotides (gapmeRs) that have been 
used for highly efficient inhibition of lncRNA function [59,74,75]. Meg3 
knockdown by intravenous delivery of Meg3 gapmeRs induced the 
expression of p53 target genes GADD45A and RRAD by 2.4- and 1.7-fold, 
respectively, in ECs isolated from the livers (Fig. 3A). Meg3 knockdown 
also induced the expression of cyclin-dependent kinase inhibitors 
including two markers of senescence [76–78] CDKN1A (encoding p21) 
by 2.7-fold and CDKN2A (encoding p16) by 3.4-fold, in the ECs isolated 
from the livers of obese mice (Fig. 3A). In the ECs isolated from skeletal 
muscles, GADD45A is the only induced gene among these examined 
genes, and its expression was elevated by 1.7-fold (Fig. 3A). In the ECs 
isolated from the eWATs, CDKN2A is the only induced gene, and its 
expression was elevated by 2.0-fold (Fig. 3A). These changes in gene 
expression were associated with a 94.3%, 90.0%, and 75.2% reduction 
of Meg3 expression in the ECs isolated from the liver, skeletal muscle, 
and eWAT, respectively (Fig. 3B). The expression of p21 was also 
examined by immunostaining on frozen liver sections. Meg3 knockdown 
led to a 10.3-fold increase in the number of p21-positive cells that 
co-localize with CD31-positive cells in the livers of obese mice (Fig. 3C). 
Fig. 1. LncRNA Meg3 expression is induced in 
vascular endothelium of obese mice. (A) Workflow of 
genome-wide RNA-seq profiling for the identification 
of differentially expressed lncRNAs (fold change >1.5; 
FDR<0.1; mean FPKM greater than 2 in at least one 
group). (B) Heatmap displaying significantly dysre-
gulated lncRNAs identified by edgeR. (C) Meg3 
expression was detected in the ECs isolated from the 
eWATs, livers, or skeletal muscles (SM) of lean or 
obese mice by qPCR. Mice were fed a control diet or 
high-fat diet (HFD) for 4 weeks (n = 7–10 for lean and 
n = 9–12 for obese) or 8 weeks (n = 8 for lean and n 
= 8 for obese). (D) Meg3 expression was compared 
among ECs from eWATs, livers, and skeletal muscles. 
The expression of Meg3 in eWATs was set as 100 (n =
15 mice). For all panels, values are mean ± SEM; *, P 
< 0.05.   
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In the liver, skeletal muscle, and eWAT tissues with a mixed cell pop-
ulations, CDKN2A is the only gene induced by Meg3 knockdown among 
examined genes; its expression was induced by 2-fold in the liver but not 
in the skeletal muscle and eWAT (Fig. 3D). These data demonstrate that 
Meg3 knockdown promotes cellular senescence of hepatic endothelium 
with no or minimal effects on cellular senescence of other cell types in 
the liver, skeletal muscle, and eWAT. 
We next examined Meg3 expression in human liver specimens pro-
vided by the Liver Tissue Cell Distribution System at the University of 
Minnesota. Demographics of these liver specimens are shown in 
Fig. 2. Meg3 knockdown (KD) causes cellular senescence of HUVECs. HUVECs were transfected with 10 nM control gapmeRs or 10 nM Meg3 gapmeRs. (A) Fold 
change of SA-β-gal positive cells were calculated from 36 images per condition (n = 3). (B) MitoSOX reagent staining and flow cytometry analysis (n = 3). (C) Levels 
of endogenous free radicals, primarily superoxide, measured by electron paramagnetic resonance (EPR), with n = 10 or 11 replicates (n = 3). (D) Oxygen con-
sumption rate (OCR) in HUVECs (n = 3). (E) Mitochondria revealed by mitoTracker deep red in live cells. 101 or 75 cells (n = 4) were analyzed. (F) Mitochondrial 
membrane potential (ΔΨm) revealed by JC-1 staining in live cells. Data from 32 or 40 cells (n = 3). (G) Western blot analysis of p62 and LC3-II in the presence or 
absence of bafilomycin A1 (Baf A1) (n = 3). N.S., non-significant. (H) Fold change of SA-β-gal positive cells were calculated from 30 images per condition in the 
presence or absence of rapamycin (n = 3). For all panels, values are mean ± SEM; n = 3 refers to three independent experiments; *, P < 0.05. (For interpretation of 
the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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Supplementary Table 2. Nonalcoholic steatohepatitis (NASH) is the 
more aggressive form of nonalcoholic fatty liver disease (NAFLD). Meg3 
expression was elevated by 1.6- and 1.9-fold, respectively, in NAFLD and 
NASH livers (Fig. 3E). Furthermore, CDKN1A expression was 1.8-fold 
higher in NAFLD and 2.4-fold higher in NASH livers, respectively; and 
the expression of CDKN2A was 8.8-fold higher in NASH livers (Fig. 3E). 
Importantly, the expression of Meg3 positively correlates with CDKN2A 
expression in these human liver specimens (Fig. 3E). 
Taken together, these data suggest endogenous Meg3 limits cell 
senescence of hepatic vascular endothelium in diet-induced obese mice 
and has translational relevance to human subjects, although additional 
features of cellular senescence such as impaired autophagy and mito-
chondrial structure and function were not examined in hepatic endo-
thelium in the present study. 
3.4. Meg3 knockdown impairs insulin signaling and glucose homeostasis 
Senescent cells are found in obesity [78–81]. Because we found Meg3 
knockdown promotes cellular senescence in hepatic endothelium in 
obesity, we next sought to examine the role of Meg3 in obesity-induced 
insulin resistance and glucose homeostasis. The intravenous delivery of 
Meg3 gapmeRs led to 94.8%, 89.8%, and 68.9% reduction of Meg3 
expression in the liver, skeletal muscle, and eWAT, respectively 
(Fig. 4A). Meg3 knockdown did not affect food intake, body weight, 
physical activity, heat, carbon dioxide production, or oxygen con-
sumption revealed by metabolic cage studies (Fig. S4). Glucose tolerance 
test (GTT) and insulin tolerance test (ITT) revealed that Meg3 
gapmeR-treated mice developed more severe glucose intolerance and 
insulin resistance after being fed a HFD for 10 weeks (Fig. 4B and C). In 
addition, Meg3 gapmeRs-treated mice had higher fasting plasma insulin 
Fig. 3. Meg3 knockdown (KD) causes cellular senescence in hepatic vascular endothelium in obesity. (A–D) C57BL/6 mice were fed on a HFD and treated with 
control gapmeRs (n = 6) or Meg3 gapmeRs (n = 7) as described in Methods. (A) The expression of senescent markers (CDKN1A and CDKN2A) and p53 target genes 
(GADD45A and RRAD) were examined in the freshly isolated ECs of livers, skeletal muscles (SM), and eWATs by qPCR. (B) The expression of Meg3 were examined in 
isolated ECs by qPCR. (C) Immunofluorescence staining of liver sections with anti-CD31 and anti-p21 antibodies. The percentage of p21 positive cells was calculated 
among CD31 positive cells, which was set as 1 in mice injected with control gapmeRs. Several double positive cells are indicated by arrowheads. (D) The expression of 
senescent markers (CDKN1A and CDKN2A) and p53 target genes (GADD45A and RRAD) were examined in livers, skeletal muscles, and eWATs tissues by qPCR. (E) 
The expressions of Meg3, CDKN1A, and CDKN2A were analyzed in RNAs isolated from liver specimens of human subjects without fatty liver (n = 7), with nonalcohlic 
fatty liver (NAFLD; n = 5) or nonalcohlic hepatosteatosis (NASH, the severe form of fatty liver; n = 7). For all panels, values are mean ± SEM; *, P < 0.05. 
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levels but not adiponectin (Fig. 4D). To ensure these findings are linked 
to changes in insulin signaling, we examined Akt phosphorylation at 
serine 473 (pSer473-Akt) in the liver, skeletal muscle, and eWAT of 
obese mice injected with insulin. Meg3 knockdown reduced the levels of 
pSer473-Akt by 43% in the livers and by 32% in the skeletal muscles but 
not in the eWATs in obese mice (Fig. 4E). We also examined the effects of 
Meg3 knockdown on the levels of phosphorylated insulin receptor β 
subunit (IRβ), a key upstream component of insulin signaling cascade. 
Meg3 knockdown reduced the levels of phosphorylated IRβ by 50% in 
the livers of obese mice (Fig. S5). These data demonstrate that Meg3 
knockdown impairs systemic glucose homeostasis and insulin sensitivity 
in the liver and skeletal muscle. 
Chronic inflammation is a key driver of obesity-induced insulin 
resistance [82–84]. Histological assessment of eWAT by macrophage 
marker Mac2 revealed no differences between two groups of obese mice 
injected with negative control or Meg3 gapmeRs (Fig. S6A). The 
expression of TNF-α and ICAM-1 was unaltered at the mRNA levels in 
eWAT (Fig. S6B). Interestingly, histological assessment of livers by CD68 
staining revealed a 37% decrease in macrophage content in the HFD-fed 
mice injected with Meg3 gapmeRs compared to livers of the HFD-fed 
control mice (Fig. S6C). The mRNA expression of CD68 and F4/80 
were also reduced, while the mRNA expression of MCP1 was unchanged 
(Fig. S6D). In addition, the plasma levels of TNF-α and MCP1 were not 
changed in mice with Meg3 knockdown (Fig. S6E), suggesting that Meg3 
Fig. 4. Meg3 knockdown (KD) induces obesity-associated insulin resistance. C57BL/6 mice were fed a HFD. At Week 5 on HFD, mice were intravenously injected 
with control gapmeRs or Meg3 gapmeRs once a week and maintained on HFD up to 12 weeks. (A) Meg3 expression was examined in livers, skeletal muscles, and 
eWATs tissues by qPCR. (B) Glucose and insulin tolerance tests. (C) Areas under curves (AUC) for GTT and ITT. (D) The fasting levels of plasma insulin and adi-
ponectin were examined by ELISA. A small amount of blood were collected before insulin injection. (E) Total Akt and the phosphorylation of Akt at serine 473 were 
examined by western blot in the indicated tissues of overnight-fasted mice. The tissues were collected at 10 min after insulin injection (0.75 units/kg). For all panels, 
values are mean ± SEM, n = 6–7; *, P < 0.05. 
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knockdown had no effects on systemic inflammation. Finally, the levels 
of plasma ALT and AST were not changed by Meg3 knockdown 
(Fig. S6F). But interestingly, Meg3 knockdown induced type I interferon 
response in hepatic endothelium as revealed by the induction of IFN-β 
and IRGM (immunity-related GTPase family M) expression at mRNA 
levels (Fig. S6G). Consistent with the data, Meg3 knockdown also 
induced type I interferon response in HUVECs (Fig. S6G). These data 
demonstrate that Meg3 knockdown-induced insulin resistance is un-
likely to arise from its effects on systemic inflammation. 
To interrogate the proteome regulated by Meg3 in vivo, livers were 
collected for quantitative proteomics analysis (Fig. S7). TMT10-plex 
labeling and mass spectrometry identified 104 differentially expressed 
proteins (20% change with P < 0.05) (Supplementary Table 3). Genes 
encoding these proteins were used for gene ontology (GO) term analysis. 
The top 10 GO terms by fold enrichment are shown in Fig. S7. The top 
three terms are “Mitochondrial respiratory chain complex I′′, “Respira-
tory chain”, and “Response to oxidative stress”, indicating that Meg3 
knockdown impairs mitochondrial function in liver of obese mice. These 
data suggest that Meg3 knockdown induces mitochondrial stress in vivo. 
Taken together, these data demonstrate that Meg3 knockdown im-
pairs systemic glucose homeostasis and insulin signaling in the liver and 
skeletal muscle independent of its any effects on systemic inflammation. 
3.5. Endothelial cell-specific p53 knockout attenuates Meg3 knockdown- 
induced cellular senescence in hepatic endothelium 
An important question that we wished to address is whether cellular 
senescence of the vascular endothelium impairs glucose homeostasis 
and insulin signaling in obesity. Our data demonstrate that Meg3 
knockdown induced hepatic endothelial senescence which is associated 
with impaired glucose homeostasis and insulin signaling (Figs. 3 and 4), 
but the cause-effect relationship between them has not been established. 
Here, we examined whether p53 deficiency in endothelium can 
attenuate cellular senescence in hepatic endothelium induced by Meg3 
knockdown because p53 is a master regulator of cellular senescence and 
glucose homeostasis [85,86]. We took a genetic approach to reduce p53 
expression in the vascular endothelium. We used conditional p53 floxed 
mice carrying tamoxifen-inducible Cre-recombinase under the regula-
tion of the vascular endothelial cadherin promoter (p53 iECKO). The 
deletion of the p53 gene in endothelium was induced by tamoxifen in-
jection, leading to 45% and 87% decrease in p53 expression in hepatic 
and skeletal muscle ECs, respectively, after 12 weeks (Fig. S8A). In 
Fig. 5. Endothelial cell-specific p53 deletion attenuates Meg3 knockdown-induced cellular senescence of hepatic endothelium in obese mice. (A–C) p53 iECKO mice 
were fed a HFD. At Week 5 on HFD, mice were intravenously injected with control gapmeRs or Meg3 gapmeRs (knockdown) once a week and maintained on HFD for 
up to 12 weeks (n = 6–8 per group). (A) The expression of senescent markers (CDKN1A and CDKN2A) and p53 target genes (GADD45A and RRAD) were examined in 
the freshly isolated ECs by qPCR. (B) The expression of senescent markers (CDKN1A and CDKN2A) and p53 target genes (GADD45A and RRAD) were examined in 
livers and skeletal muscles (SM) tissues by qPCR. (C) Immunofluorescence staining of liver sections with anti-CD31 and anti-p21 antibodies. Arrowheads indicate 
double positive cells. (D–E) p53 floxed mice (p53fl/fl) were fed a HFD. At Week 5 on HFD, mice were intravenously injected with control gapmeRs or Meg3 gapmeRs 
once a week and maintained on HFD for up to 12 weeks (n = 6–9 per group). (D) The expression of senescent markers (CDKN1A and CDKN2A) and p53 target genes 
(GADD45A and RRAD) were examined in the freshly isolated ECs by qPCR. (E) The expression of senescent markers (CDKN1A and CDKN2A) and p53 target genes 
(GADD45A and RRAD) were examined in livers by qPCR. (F) SA-β-gal staining of HUVECs transduced with control lentivirus (shRNA-ctl) or lentivirus expressing p53 
shRNA (shRNA-p53), and transfected with control gapmeRs or Meg3 gapmeRs. The percentages of SA-β-gal positive cells were analyzed and fold changes were 
calculated relative to that in HUVECs transduced with shRNA-ctl and transfected with control gapmeRs. Data were from three independent experiments. For all 
panels, values are mean ± SEM; *, P < 0.05. 
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addition, the expression of p53 was reduced by 64% at protein levels in 
the freshly isolated liver ECs of p53 iECKO mice (Fig. S8B), which 
remarkably attenuated the expression of p21 at mRNA levels (Fig. S8C). 
In contrast, the expression of p53 was not changed in the livers and 
skeletal muscles (Fig. S8D). Systemic delivery of Meg3 gapmeRs reduced 
the expression of Meg3 in both ECs and liver and skeletal muscle tissues 
in either p53 iECKO (CadCreERT2:p53fl/fl) mice (Fig. S8E) or p53fl/fl 
mice (data not shown). 
We first examined the effects of Meg3 knockdown on cellular 
senescence of hepatic endothelium in p53 iECKO mice (Fig. 5A–C). In 
the ECs isolated from the livers, p53 deletion completely blocked the 
induction of CDKN1A, GADD45A, and RRAD in p53 iECKO mice injected 
with Meg3 gapmeRs as compared with that in mice injected with 
negative control gapmeRs (Fig. 5A). Interestingly, the expression of 
CDKN2A was still induced by Meg3 knockdown despite p53 deletion 
(Fig. 5A). In the liver tissue, CDKN2A and RRAD were induced by 2.5- 
and 1.7-fold, respectively (Fig. 5B). In the ECs isolated from the skeletal 
muscles, p53 deletion blocked the induction of GADD45A by Meg3 
knockdown (Fig. 5A). The expression of all examined genes was not 
changed in the skeletal muscle (Fig. 5B). Of note, p21 expression was 
barely detectable by qPCR and immunostaining in both groups of mice 
(Fig. 5C, Fig. S8C), likely due to the deletion of p53. 
We next examined the effects of Meg3 knockdown on cellular 
senescence of hepatic endothelium in p53fl/fl mice (Fig. 5D and E). 
Consistent with the data shown in Fig. 3, Meg3 knockdown causes 
cellular senescence in hepatic endothelium in obese p53fl/fl mice. Spe-
cifically, the expression of CDKN1A, CDKN2A, and GADD45A was 
elevated by 1.5-fold, 2.3-fold, and 1.4-fold, respectively, in the ECs 
isolated from the livers of obese p53fl/fl mice (Fig. 5D). The expression of 
RRAD was not changed in this experiment probably because p53fl/fl mice 
were less obese than those in Fig. 3. 
We also examined the effects of p53 on Meg3 knockdown-induced EC 
senescence revealed by SA-β-gal activity staining. The expression of p53 
was dramatically reduced by lentiviral p53 shRNA in HUVECs (data not 
shown). Meg3 knockdown led to a 1.6-fold increase in the number of SA- 
β-gal positive cells in HUVECs transduced with lentiviral control 
shRNAs, which was abolished in HUVECs transduced with lentiviral p53 
shRNA (Fig. 5F). 
Taken together, our data demonstrate p53 deletion in vascular 
endothelium can partially attenuate Meg3 knockdown-induced cellular 
senescence of hepatic vascular endothelium in diet-induced obese mice. 
3.6. Delaying the cellular senescence of hepatic endothelium by 
endothelial cell-specific p53 knockout attenuates the impaired glucose 
homeostasis and insulin signaling resulted from Meg3 knockdown 
We have shown that p53 deficiency in hepatic endothelium can 
attenuate Meg3 knockdown-induced cellular senescence in the hepatic 
Fig. 6. Endothelial cell-specific p53 deletion attenuates Meg3 knockdown-impaired insulin signaling. (A–B) p53 iECKO mice were fed a HFD. At Week 5 on HFD, 
mice were intravenously injected with control gapmeRs or Meg3 gapmeRs (knockdown) once a week and maintained on HFD for up to 12weeks (n = 6–8 per group). 
(A) Glucose and insulin tolerance tests. (B) Total Akt and phosphorylated Akt at serine 473 were examined by western blot in the livers and skeletal muscles (SM) of 
overnight-fasted mice. The tissues were collected at 10 min after insulin injection (0.75 units/kg). (C–E) p53 floxed (p53fl/fl) mice were fed a HFD. At Week 5 on HFD, 
mice were intravenously injected with control gapmeRs or Meg3 gapmeRs once a week and maintained on HFD for up to 12 weeks (n = 5–8 per group). (C) Glucose 
and insulin tolerance tests. (D) Areas under curves (AUC) for GTT and ITT. (E) Total Akt and phosphorylated Akt at serine 473 were examined by western blot in the 
livers of overnight-fasted mice. The livers were collected at 10 min after insulin injection (0.75 units/kg). For all panels, values are mean ± SEM; *, P < 0.05. 
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endothelium of obese mice. We next examined the role of cellular 
senescence of hepatic endothelium in glucose homeostasis and insulin 
signaling in obesity. Glucose tolerance test (GTT) and insulin tolerance 
test (ITT) revealed that Meg3 gapmeR-treated mice did not develop 
more severe glucose intolerance and insulin resistance after being fed a 
HFD for 10 weeks (Fig. 6A), when p53 expression was absent in hepatic 
endothelium. Next, we examined the effects of Meg3 knockdown on the 
phosphorylation of Akt at serine 473 in the livers and skeletal muscles of 
p53 iECKO mice (Fig. 6B). We did not examine the effect of Meg3 
knockdown in eWAT in p53 iECKO mice, because Meg3 knockdown did 
not affect the phosphorylation of Akt in eWAT (Fig. 4E). The deletion of 
p53 in the vascular endothelium restored the phosphorylation of Akt in 
p53 iECKO mice injected with Meg3 gapmeRs to a level comparable to 
that observed in p53 iECKO mice injected with negative control gapm-
eRs in both liver and skeletal muscle (Fig. 6B). Consistent with the data 
in C57BL/6 mice (Fig. 4), Meg3 knockdown impaired glucose homeo-
stasis and insulin signaling revealed by GTT, ITT, and western blot 
analysis of Akt phosphorylation at serine 473 in p53 floxed mice 
(Fig. 6C–E). Similarly, Meg3 knockdown also reduced the levels of 
phosphorylated IRβ by 25% (Fig. S9). These data demonstrate that the 
attenuation of cellular senescence of hepatic endothelium by deleting 
p53 expression can restore impaired glucose homeostasis and insulin 
signaling in obesity, suggesting that cellular senescence of hepatic 
endothelium drives obesity-induced insulin resistance and dysregulation 
of glucose homeostasis. 
4. Discussion 
In the present study, we examined the role of Meg3 in cellular 
senescence of HUVECs in vitro, and cellular senescence of hepatic 
endothelium, glucose homeostasis, and insulin signaling in diet-induced 
obesity. Our data demonstrate that: 1) Meg3 knockdown induces 
endothelial senescence in vitro and cellular senescence of hepatic 
endothelium in obese mice; 2) Meg3 knockdown impairs insulin 
signaling and glucose homeostasis in obesity; and 3) hepatic endothelial 
senescence promotes obesity-induced insulin resistance. Therefore, 
Meg3 expression in the vascular endothelium maintains glucose ho-
meostasis and insulin signaling by protecting the hepatic endothelium 
against cellular senescence in obesity. 
Cellular senescence is characterized by a number of hallmarks, 
including mitochondrial dysfunction, DNA damage, and increased 
expression of cyclin-dependent kinase inhibitors and SA-β-gal activity 
[1,4,87,88]. As we have shown that Meg3 knockdown inhibits cell 
proliferation, induces DNA damage [23], and others have shown that 
Meg3 knockdown decreases the length of telomeres in HUVECs [60], we 
wished to examine further markers of cellular senescence to firmly 
establish Meg3 as an important player in cellular senescence. We 
examined senescent hallmarks including SA-β-gal activity, mitochon-
drial dysfunction, and autophagy (Fig. 2). Our data strongly demon-
strate that Meg3 prevents endothelial senescence in vitro. Importantly, 
we found Meg3 knockdown causes cellular senescence in hepatic 
vascular endothelium in obese mice (Fig. 3). In addition, the expression 
of Meg3 positively correlates with CDKN2A expression in human liver 
specimens (Fig. 3E). CDKN2A encodes p16, a commonly used marker of 
cellular senescence in vivo [3,77,78]. Meg3 expression was elevated by 
1.6- and 1.9-fold, respectively, in NAFLD and NASH livers (Fig. 3E), 
suggesting that Meg3 induction is likely a compensatory mechanism in 
NAFLD and NASH livers in patients. Future studies will need to clarify 
this point. These data demonstrate that Meg3 is an important regulator 
of cellular senescence in vascular endothelium, which has not been 
previously reported. 
While the precise mechanisms by which Meg3 knockdown induces 
cellular senescence are not fully elucidated, regulation of downstream 
p53 signaling and autophagy likely contribute. In support, we showed 
that p53 knockdown can block Meg3 knockdown-induced SA-β-gal ac-
tivity (Fig. 5F), and the activation of autophagy by rapamycin can also 
attenuate Meg3 knockdown-induced SA-β-gal activity (Fig. 2H) in 
HUVECs. It is possible that Meg3 knockdown induces cellular senes-
cence by impairing autophagy which results from the activation of p53 
signaling upon Meg3 knockdown. It is also possible that Meg3 knock-
down induces cellular senescence through cGAS-STING signaling, which 
can be activated in response to mitochondrial stress and DNA damage 
[89]. Indeed, Meg3 knockdown induces the expression of IFN-β and 
IRGM in hepatic endothelium in obese mice, and the expression of IFN-β 
and other interferon-stimulated genes in HUVECs (Fig. S6G), demon-
strating that Meg3 knockdown activates type I interferon response in 
vitro and in hepatic endothelium in obese mice. These findings raise the 
possibility that cGAS-STING signaling contributes to cellular senescence 
induced by Meg3 knockdown in vitro and in vivo. Further studies are 
required to tease out the underlying molecular mechanism. One limi-
tation to our data on Meg3’s role in cellular senescence is that HUVECs 
were used for in vitro cell culture studies. Thus, our findings from 
HUVECs may not fully recapitulate the effects of Meg3 on cellular 
senescence of hepatic endothelium in obese mice. Specifically, the ef-
fects of Meg3 on additional features of cellular senescence such as 
impaired autophagy and mitochondrial structure and function were not 
examined in primary mouse liver sinusoidal ECs or in hepatic endo-
thelium of mice in the present study. Future studies are warranted to 
provide further insights into this issue. 
SQSTM1/p62 is a selective autophagy receptor that serves as a link 
between microtubule associated protein 1 light chain 3 (LC3) and 
ubiquitinated substrates of degradation [90]. During autophagy, p62, 
LC3-II (a lipidated form of LC3), and substrates become incorporated 
into autophagosomes and are degraded in autolysosomes (formed by the 
fusion of autophagosomes with lysosomes) [91]. Thus, the accumulation 
of p62 and LC3-II often correlates with impaired autophagy, while the 
reduction of p62 and LC3-II often associates with autophagy activation 
[91]. To exclude the possibility that the higher levels of p62 and LC3-II 
could activate autophagy, the expression of p62 and LC3-II needs to be 
examined in cells treated with Bafilomycin A1. It inhibits the degrada-
tion of p62 and LC3-II by blocking autophagosome-lysosome fusion and 
autolysosome acidification. When cells are treated with Bafilomycin A1, 
the persistent increase in p62 and LC3-II expression by the experimental 
condition indicates that autophagy is activated, while the normalization 
of p62 and LC3-II accumulation, respectively, between control and 
experimental conditions indicates that the accumulation of p62 and 
LC3-II results from impaired autophagy under basal condition. Our data 
in Fig. 2G demonstrate that Meg3 knockdown alters autophagic flux 
likely by impairing autophagy in HUVECs. Furthermore, we speculate 
that Meg3 knockdown leads to the accumulation of protein aggregates. 
In this study, we examined the role of Meg3 in glucose homeostasis 
and insulin signaling in obesity, which has not been previously exam-
ined by other groups. GTT and ITT revealed that Meg3 knockdown 
impairs glucose homeostasis in obesity (Fig. 4B and C). Meg3 knock-
down decreases insulin-stimulated Akt phosphorylation in livers and 
skeletal muscles (Fig. 4E), which is associated with an increase in fasting 
plasma insulin levels (Fig. 4D). In contrast, Meg3 knockdown had no 
effects on Akt phosphorylation in eWAT (Fig. 4E). The tissue-specific 
effects of other genes on Akt phosphorylation in major insulin target 
organs have been observed by other studies [92,93]. The tissue specific 
effects of Meg3 on insulin signaling could be due to the different 
microenvironment of different tissues. Chronic inflammation is a key 
driver of obesity-induced insulin resistance [82–84]. Meg3 knockdown 
had no effects on systemic inflammation (Fig. S6), suggesting Meg3 
knockdown-induced insulin resistance is unlikely caused by its effects on 
systemic inflammation. 
Obesity accelerates cellular senescence [17,94,95]. Elimination of 
p16-expressing senescent cells restored obesity-impaired neurogenesis 
and alleviated obesity-induced anxiety and metabolic dysfunction in 
obese mice [16,95]. However, the causal relationship between EC 
senescence and insulin resistance has not been examined in obesity. To 
answer the question, we employed a genetic approach to attenuate Meg3 
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knockdown-induced cellular senescence in obese mice. Specifically, we 
used Cdh5CreERT2 Cre mice [24,25] to excise the floxed p53 exon in our 
studies. These mice express Cre driven by VE-cadherin promoter that is 
tamoxifen-inducible. This mouse line is most commonly used to excise 
sequences flanked by loxP sites in vascular endothelium [96,97], 
because it has more specific labelling of ECs than other mouse lines such 
as Tie2-Cre [98]. Furthermore, it is commonly used to excise loxP-sites 
flanking sequences in hepatic endothelium [97,99–101]. EC-specific 
p53 deletion attenuates DNA damage/cell senescence in obese mice 
[102]. Indeed, we found that EC-specific p53 knockout abrogates the 
induction of p21 and other p53 target genes such as GADD45A and 
RRAD upon Meg3 knockdown in hepatic vascular endothelium 
(Fig. 5A). Meg3 knockdown-induced p16 expression still persists in 
hepatic vascular endothelium with p53 deficiency, likely due to residual 
p53 expression in hepatic vascular endothelium. Importantly, we found 
that attenuation of hepatic EC senescence by EC-specific p53 knockout 
restores the impaired glucose homeostasis and hepatic insulin signaling, 
demonstrating that hepatic cell senescence promotes and attenuation of 
hepatic cell senescence ameliorates obesity-induced insulin resistance. 
In conclusion, our data demonstrate that cellular senescence of he-
patic endothelium promotes obesity-induced insulin resistance, which is 
tightly regulated by the expression of Meg3. Our data suggest that 
manipulation of Meg3 expression may represent a novel approach to 
managing obesity-associated hepatic endothelial senescence and insulin 
resistance. 
Author contributions 
X.C. and M.S.S. performed experiments and analysis. M.M., S.L.S, 
and M.C.Z. assisted with data analysis. X.S. and M.W.F. were involved in 
conceptualization. M.P.V. contributed to mitochondrial function 
assessment experiments, O.K. made intellectual contributions and hel-
ped to analyze and interpret the data. X.S. and X.C. wrote the paper. M. 
W.F. and M.C.Z. were involved in editing. X.S. and M.W.F. provided 
funds. All authors critically reviewed the manuscript. 
Declaration of competing interest 
The authors declare no competing financial or non-financial 
interests. 
Acknowledgements 
We thank Dr. Reinier Boon and Dr. Stefanie Dimmeler for providing 
the target sequence of human and mouse Meg3 gapmeRs, Dr. Jason C. 
Kovacic for providing Cdh5CreERT2 Cre mice, Dr. Mi-Jeong Lee and Dr. 
Susan K. Fried for providing unidentified human white adipose tissues, 
and technologists Emily Barber and Mengna Xia at the Biomedical and 
Obesity Research Core of the Nebraska Center for Prevention of Obesity 
Diseases for assisting with mouse metabolic cage studies. Proteomics 
experiments in Fig. S7 were carried out by the Proteomics and Mass 
Spectrometry Core facility at Princeton University. EPR Spectroscopy 
data (Fig. 2C) was collected in the University of Nebraska’s EPR Spec-
troscopy Core, which was established, in part, by a grant from the Na-
tional Institute of General Medical Sciences of the National Institutes of 
Health (P30GM103335) awarded to the University of Nebraska’s Redox 
Biology Center. This work was supported by the National Institutes of 
Health Funded COBRE grant 1P20GM104320 [X.S. through the 
Nebraska Center for the Prevention of Obesity-related Diseases through 
Dietary Molecules], the American Heart Association 
SDG#15SDG25400012 [to X.S.] and 18SFRN33900144 [to M.W.F.], 
and the National Institutes of Health Funded T32 grant 5T32GM107001- 
04 [to M.M.]. This work was also supported by the National Institutes of 
Health [HL150536 to X.S.; HL115141, HL134849, HL148207, 
HL148355, and HL153356 to M.W.F.; GM108975 and GM131701-01 to 
O.K.; P30GM103335 to the University of Nebraska’s Redox Biology 
Center; and NIH Contract # HSN276201200017C to the Liver Tissue 
Cell Distribution System.]; and the Pilot and Feasibility Program [to X. 
S.] from Boston Nutrition Obesity Research Center funded by NIH grant 
P30DK046200. Funding for open access charge: National Institutes of 
Health. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.redox.2021.101863. 
References 
[1] A. Hernandez-Segura, J. Nehme, M. Demaria, Hallmarks of cellular senescence, 
Trends Cell Biol. 28 (6) (2018) 436–453. 
[2] D. Munoz-Espin, M. Serrano, Cellular senescence: from physiology to pathology, 
Nat. Rev. Mol. Cell Biol. 15 (7) (2014) 482–496. 
[3] N.E. Sharpless, C.J. Sherr, Forging a signature of in vivo senescence, Nat. Rev. 
Canc. 15 (7) (2015) 397–408. 
[4] N. Herranz, J. Gil, Mechanisms and functions of cellular senescence, J. Clin. 
Invest. 128 (4) (2018) 1238–1246. 
[5] A. Hernandez-Segura, et al., Unmasking transcriptional heterogeneity in 
senescent cells, Curr. Biol. : Cailiao Baohu 27 (17) (2017) 2652–2660.e4. 
[6] A. Hernandez-Segura, R. Rubingh, M. Demaria, Identification of stable 
senescence-associated reference genes, Aging Cell 18 (2) (2019), e12911. 
[7] P. Lecot, F. Alimirah, P.Y. Desprez, J. Campisi, C. Wiley, Context-dependent 
effects of cellular senescence in cancer development, Br. J. Canc. 114 (11) (2016) 
1180–1184. 
[8] M. Storer, et al., Senescence is a developmental mechanism that contributes to 
embryonic growth and patterning, Cell 155 (5) (2013) 1119–1130. 
[9] D. Munoz-Espin, et al., Programmed cell senescence during mammalian 
embryonic development, Cell 155 (5) (2013) 1104–1118. 
[10] M. Demaria, et al., An essential role for senescent cells in optimal wound healing 
through secretion of PDGF-AA, Dev. Cell 31 (6) (2014) 722–733. 
[11] T. Feng, et al., CCN1-Induced cellular senescence promotes heart regeneration, 
Circulation 139 (21) (2019) 2495–2498. 
[12] R. Sarig, et al., Transient p53-mediated regenerative senescence in the injured 
heart, Circulation 139 (21) (2019) 2491–2494. 
[13] T.J. Bussian, et al., Clearance of senescent glial cells prevents tau-dependent 
pathology and cognitive decline, Nature 562 (7728) (2018) 578–582. 
[14] D.J. Baker, et al., Naturally occurring p16(Ink4a)-positive cells shorten healthy 
lifespan, Nature 530 (7589) (2016) 184–189. 
[15] P.J. Thompson, et al., Targeted elimination of senescent beta cells prevents type 1 
diabetes, Cell Metabol. 29 (5) (2019) 1045–1060.e10. 
[16] A.K. Palmer, et al., Targeting senescent cells alleviates obesity-induced metabolic 
dysfunction, Aging Cell 18 (3) (2019), e12950. 
[17] D.G.A. Burton, R.G.A. Faragher, Obesity and type-2 diabetes as inducers of 
premature cellular senescence and ageing, Biogerontology 19 (6) (2018) 
447–459. 
[18] N. Jae, A.W. Heumuller, Y. Fouani, S. Dimmeler, Long non-coding RNAs in 
vascular biology and disease, Vasc. Pharmacol. 114 (2019) 13–22. 
[19] V. Simion, S. Haemmig, M.W. Feinberg, LncRNAs in vascular biology and disease, 
Vasc. Pharmacol. 114 (2019) (2018) 145–156. 
[20] S. Haemmig, et al., Long noncoding RNA SNHG12 integrates a DNA-PK-mediated 
DNA damage response and vascular senescence, Sci. Transl. Med. 12 (531) (2020) 
eaaw1868. 
[21] T. Weirick, G. Militello, S. Uchida, Long non-coding RNAs in endothelial biology, 
Front. Physiol. 9 (2018) 522. 
[22] A. Leung, V. Amaram, R. Natarajan, Linking diabetic vascular complications with 
LncRNAs, Vasc. Pharmacol. 114 (2019) (2018) 139–144. 
[23] M.S. Shihabudeen Haider Ali, et al., LncRNA Meg3 protects endothelial function 
by regulating the DNA damage response, Nucleic Acids Res. 47 (3) (2019) 
1505–1522. 
[24] I. Sorensen, R.H. Adams, A. Gossler, DLL1-mediated Notch activation regulates 
endothelial identity in mouse fetal arteries, Blood 113 (22) (2009) 5680–5688. 
[25] Y. Wang, et al., Ephrin-B2 controls VEGF-induced angiogenesis and 
lymphangiogenesis, Nature 465 (7297) (2010) 483–486. 
[26] M. Konishi, et al., Endothelial insulin receptors differentially control insulin 
signaling kinetics in peripheral tissues and brain of mice, Proc. Natl. Acad. Sci. U. 
S. A. 114 (40) (2017) E8478–E8487. 
[27] D.S. Ghorpade, et al., Hepatocyte-secreted DPP4 in obesity promotes adipose 
inflammation and insulin resistance, Nature 555 (7698) (2018) 673–677. 
[28] D.J. Pedersen, et al., A major role of insulin in promoting obesity-associated 
adipose tissue inflammation, Mol Metab 4 (7) (2015) 507–518. 
[29] Y.A. An, et al., Dysregulation of amyloid precursor protein impairs adipose tissue 
mitochondrial function and promotes obesity, Nat Metab 1 (12) (2019) 
1243–1257. 
[30] X. Li, Mechanisms by which adiponectin reverses high fat diet-induced insulin 
resistance in mice, Proc. Natl. Acad. Sci. U.S.A. 117 (51) (2020) 32584–32593. 
[31] M. Kleinert, et al., Animal models of obesity and diabetes mellitus, Nat. Rev. 
Endocrinol. 14 (3) (2018) 140–162. 
X. Cheng et al.                                                                                                                                                                                                                                   
Redox Biology 40 (2021) 101863
13
[32] R.J. Roth Flach, et al., Endothelial protein kinase MAP4K4 promotes vascular 
inflammation and atherosclerosis, Nat. Commun. 6 (2015) 8995. 
[33] X. Sun, et al., MicroRNA-181b improves glucose homeostasis and insulin 
sensitivity by regulating endothelial function in white adipose tissue, Circ. Res. 
118 (5) (2016) 810–821. 
[34] Y.C. Lim, et al., Heterogeneity of endothelial cells from different organ sites in T- 
cell subset recruitment, Am. J. Pathol. 162 (5) (2003) 1591–1601. 
[35] C.H. Chou, et al., Lysophosphatidic acid alters the expression profiles of 
angiogenic factors, cytokines, and chemokines in mouse liver sinusoidal 
endothelial cells, PloS One 10 (3) (2015), e0122060. 
[36] J.R. van Beijnum, M. Rousch, K. Castermans, E. van der Linden, A.W. Griffioen, 
Isolation of endothelial cells from fresh tissues, Nat. Protoc. 3 (6) (2008) 
1085–1091. 
[37] C.S. Stein, et al., Mitoregulin: a lncRNA-encoded microprotein that supports 
mitochondrial supercomplexes and respiratory efficiency, Cell Rep. 23 (13) 
(2018) 3710–3720.e8. 
[38] T. Issitt, et al., Neuropilin-1 controls endothelial homeostasis by regulating 
mitochondrial function and iron-dependent oxidative stress, iScience 11 (2019) 
205–223. 
[39] Y.M. Kim, et al., Redox regulation of mitochondrial fission protein drp1 by 
protein disulfide isomerase limits endothelial senescence, Cell Rep. 23 (12) 
(2018) 3565–3578. 
[40] M.E. Kauffman, et al., MitoSOX-Based flow cytometry for detecting mitochondrial 
ROS, React Oxyg Species (Apex) 2 (5) (2016) 361–370. 
[41] P. Mukhopadhyay, et al., Simultaneous detection of apoptosis and mitochondrial 
superoxide production in live cells by flow cytometry and confocal microscopy, 
Nat. Protoc. 2 (9) (2007) 2295–2301. 
[42] A.J. Case, S. Li, U. Basu, J. Tian, M.C. Zimmerman, Mitochondrial-localized 
NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons, 
Am. J. Physiol. Heart Circ. Physiol. 305 (1) (2013) H19–H28. 
[43] A.J. Case, C.T. Roessner, J. Tian, M.C. Zimmerman, Mitochondrial superoxide 
signaling contributes to norepinephrine-mediated T-lymphocyte cytokine 
profiles, PloS One 11 (10) (2016), e0164609. 
[44] B. Langmead, C. Trapnell, M. Pop, S.L. Salzberg, Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome, Genome Biol. 10 (3) 
(2009) R25. 
[45] D. Kim, et al., TopHat2: accurate alignment of transcriptomes in the presence of 
insertions, deletions and gene fusions, Genome Biol. 14 (4) (2013) R36. 
[46] B. Langmead, S.L. Salzberg, Fast gapped-read alignment with Bowtie 2, Nat. 
Methods 9 (4) (2012) 357–359. 
[47] D.R. Zerbino, et al., Ensembl 2018, Nucleic Acids Res. 46 (D1) (2018) 
D754–D761. 
[48] C. Trapnell, et al., Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation, Nat. 
Biotechnol. 28 (5) (2010) 511–515. 
[49] C. Trapnell, et al., Differential analysis of gene regulation at transcript resolution 
with RNA-seq, Nat. Biotechnol. 31 (1) (2013) 46–53. 
[50] M.D. Robinson, D.J. McCarthy, G.K. Smyth, edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data, Bioinformatics 26 
(1) (2010) 139–140. 
[51] R Core Development Team, R: A Language and Environment for Statistical 
Computing, R Foundation for Statistical Computing, Vienna, Austria), 2018. 
[52] D.J. McCarthy, Y. Chen, G.K. Smyth, Differential expression analysis of 
multifactor RNA-Seq experiments with respect to biological variation, Nucleic 
Acids Res. 40 (10) (2012) 4288–4297. 
[53] S. Anders, et al., Count-based differential expression analysis of RNA sequencing 
data using R and Bioconductor, Nat. Protoc. 8 (9) (2013) 1765–1786. 
[54] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real- 
time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods 25 (4) 
(2001) 402–408. 
[55] O.M. Koval, et al., Loss of MCU prevents mitochondrial fusion in G1-S phase and 
blocks cell cycle progression and proliferation, Sci. Signal. 12 (579) (2019) 
eaav1439. 
[56] R.A. Merrill, K.H. Flippo, S. Strack, Measuring mitochondrial shape with ImageJ. 
Techniques to investigate mitochondrial Function in neurons, in: S. Strack, Y. 
M. Usachev (Eds.), Springer New York, New York, NY), 2017, pp. 31–48. 
[57] R.A. Boon, et al., Long noncoding RNA Meg3 controls endothelial cell aging and 
function: implications for regenerative angiogenesis, J. Am. Coll. Cardiol. 68 (23) 
(2016) 2589–2591. 
[58] P. Fuschi, et al., Central role of the p53 pathway in the noncoding-RNA response 
to oxidative stress, Aging 9 (12) (2017) 2559–2586. 
[59] P. Neumann, et al., The lncRNA GATA6-AS epigenetically regulates endothelial 
gene expression via interaction with LOXL2, Nat. Commun. 9 (1) (2018) 237. 
[60] Y. Lan, et al., Long noncoding RNA MEG3 prevents vascular endothelial cell 
senescence by impairing miR-128-dependent Girdin downregulation, Am. J. 
Physiol. Cell Physiol. 316 (6) (2019) C830–C843. 
[61] F. Debacq-Chainiaux, J.D. Erusalimsky, J. Campisi, O. Toussaint, Protocols to 
detect senescence-associated beta-galactosidase (SA-betagal) activity, a 
biomarker of senescent cells in culture and in vivo, Nat. Protoc. 4 (12) (2009) 
1798–1806. 
[62] B.G. Childs, et al., Senescent intimal foam cells are deleterious at all stages of 
atherosclerosis, Science 354 (6311) (2016) 472–477. 
[63] J. Chapman, E. Fielder, J.F. Passos, Mitochondrial dysfunction and cell 
senescence: deciphering a complex relationship, FEBS Lett. 593 (13) (2019) 
1566–1579. 
[64] C.D. Wiley, et al., Mitochondrial dysfunction induces senescence with a distinct 
secretory phenotype, Cell Metabol. 23 (2) (2016) 303–314. 
[65] D.V. Ziegler, C.D. Wiley, M.C. Velarde, Mitochondrial effectors of cellular 
senescence: beyond the free radical theory of aging, Aging Cell 14 (1) (2015) 1–7. 
[66] P.V.S. Vasileiou, et al., Mitochondrial homeostasis and cellular senescence, Cells 
8 (7) (2019) 686. 
[67] A. Kopacz, et al., Keap1 governs ageing-induced protein aggregation in 
endothelial cells, Redox Biol 34 (2020), 101572. 
[68] X. Sun, E.N. Harris, New aspects of hepatic endothelial cells in physiology and 
nonalcoholic fatty liver disease, Am. J. Physiol. Cell Physiol. 318 (6) (2020) 
C1200–C1213. 
[69] S. Collins, T.L. Martin, R.S. Surwit, J. Robidoux, Genetic vulnerability to diet- 
induced obesity in the C57BL/6J mouse: physiological and molecular 
characteristics, Physiol. Behav. 81 (2) (2004) 243–248. 
[70] C.Y. Wang, J.K. Liao, A mouse model of diet-induced obesity and insulin 
resistance, Methods Mol. Biol. 821 (2012) 421–433. 
[71] L.M. Williams, et al., The development of diet-induced obesity and glucose 
intolerance in C57BL/6 mice on a high-fat diet consists of distinct phases, PloS 
One 9 (8) (2014), e106159. 
[72] R.S. Surwit, C.M. Kuhn, C. Cochrane, J.A. McCubbin, M.N. Feinglos, Diet-induced 
type II diabetes in C57BL/6J mice, Diabetes 37 (9) (1988) 1163–1167. 
[73] M.S. Winzell, B. Ahren, The high-fat diet-fed mouse: a model for studying 
mechanisms and treatment of impaired glucose tolerance and type 2 diabetes, 
Diabetes 53 (3) (2004) S215–S219. 
[74] E. Leucci, et al., Melanoma addiction to the long non-coding RNA SAMMSON, 
Nature 531 (7595) (2016) 518–522. 
[75] L. Natarelli, et al., miR-103 promotes endothelial maladaptation by targeting 
lncWDR59, Nat. Commun. 9 (1) (2018) 2645. 
[76] V. Krizhanovsky, et al., Senescence of activated stellate cells limits liver fibrosis, 
Cell 134 (4) (2008) 657–667. 
[77] J.Y. Liu, et al., Cells exhibiting strong p16 (INK4a) promoter activation in vivo 
display features of senescence, Proc. Natl. Acad. Sci. U. S. A. 116 (7) (2019) 
2603–2611. 
[78] M. Ogrodnik, et al., Cellular senescence drives age-dependent hepatic steatosis, 
Nat. Commun. 8 (2017) 15691. 
[79] T. Minamino, et al., A crucial role for adipose tissue p53 in the regulation of 
insulin resistance, Nat. Med. 15 (9) (2009) 1082–1087. 
[80] S.V. Brodsky, et al., Prevention and reversal of premature endothelial cell 
senescence and vasculopathy in obesity-induced diabetes by ebselen, Circ. Res. 94 
(3) (2004) 377–384. 
[81] C.Y. Wang, et al., Obesity increases vascular senescence and susceptibility to 
ischemic injury through chronic activation of Akt and mTOR, Sci. Signal. 2 (62) 
(2009) ra11. 
[82] G.S. Hotamisligil, Inflammation, metaflammation and immunometabolic 
disorders, Nature 542 (7640) (2017) 177–185. 
[83] Y.S. Lee, J. Wollam, J.M. Olefsky, An integrated view of immunometabolism, Cell 
172 (1–2) (2018) 22–40. 
[84] M.C. Petersen, G.I. Shulman, Mechanisms of insulin action and insulin resistance, 
Physiol. Rev. 98 (4) (2018) 2133–2223. 
[85] E.R. Kastenhuber, S.W. Lowe, Putting p53 in context, Cell 170 (6) (2017) 
1062–1078. 
[86] F. Kruiswijk, C.F. Labuschagne, K.H. Vousden, p53 in survival, death and 
metabolic health: a lifeguard with a licence to kill, Nat. Rev. Mol. Cell Biol. 16 (7) 
(2015) 393–405. 
[87] D.J. Baker, R.C. Petersen, Cellular senescence in brain aging and 
neurodegenerative diseases: evidence and perspectives, J. Clin. Invest. 128 (4) 
(2018) 1208–1216. 
[88] V. Gorgoulis, et al., Cellular senescence: defining a path forward, Cell 179 (4) 
(2019) 813–827. 
[89] T. Li, Z.J. Chen, The cGAS-cGAMP-STING pathway connects DNA damage to 
inflammation, senescence, and cancer, J. Exp. Med. 215 (5) (2018) 1287–1299. 
[90] V. Kirkin, V.V. Rogov, A diversity of selective autophagy receptors determines the 
specificity of the autophagy pathway, Mol. Cell 76 (2) (2019) 268–285. 
[91] D.J. Klionsky, et al., Guidelines for the use and interpretation of assays for 
monitoring autophagy (3rd edition), Autophagy 12 (1) (2016) 1–222. 
[92] J. Chung, et al., HSP72 protects against obesity-induced insulin resistance, Proc. 
Natl. Acad. Sci. U. S. A. 105 (5) (2008) 1739–1744. 
[93] E.P. Crowe, et al., Changes in the transcriptome of human astrocytes 
accompanying oxidative stress-induced senescence, Front. Aging Neurosci. 8 
(2016) 208. 
[94] M. Tencerova, et al., Obesity-associated hypermetabolism and accelerated 
senescence of bone marrow stromal stem cells suggest a potential mechanism for 
bone fragility, Cell Rep. 27 (7) (2019) 2050–2062.e6. 
[95] M. Ogrodnik, et al., Obesity-induced cellular senescence drives anxiety and 
impairs neurogenesis, Cell Metabol. 29 (5) (2019) 1233. 
[96] S. Payne, S. De Val, A. Neal, Endothelial-specific Cre mouse models, Arterioscler. 
Thromb. Vasc. Biol. 38 (11) (2018) 2550–2561. 
[97] J. Poisson, et al., Liver sinusoidal endothelial cells: physiology and role in liver 
diseases, J. Hepatol. 66 (1) (2017) 212–227. 
[98] Y. Tang, A. Harrington, X. Yang, R.E. Friesel, L. Liaw, The contribution of the Tie2 
+ lineage to primitive and definitive hematopoietic cells, Genesis 48 (9) (2010) 
563–567. 
[99] A. Hammoutene, et al., A defect in endothelial autophagy occurs in patients with 
non-alcoholic steatohepatitis and promotes inflammation and fibrosis, J. Hepatol. 
72 (3) (2020) 528–538. 
X. Cheng et al.                                                                                                                                                                                                                                   
Redox Biology 40 (2021) 101863
14
[100] M. Ruart, et al., Impaired endothelial autophagy promotes liver fibrosis by 
aggravating the oxidative stress response during acute liver injury, J. Hepatol. 70 
(3) (2019) 458–469. 
[101] B.S. Ding, et al., Inductive angiocrine signals from sinusoidal endothelium are 
required for liver regeneration, Nature 468 (7321) (2010) 310–315. 
[102] M. Yokoyama, et al., Inhibition of endothelial p53 improves metabolic 
abnormalities related to dietary obesity, Cell Rep. 7 (5) (2014) 1691–1703. 
X. Cheng et al.                                                                                                                                                                                                                                   
